Last reviewed · How we verify

Verastem, Inc. — Portfolio Competitive Intelligence Brief

Verastem, Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Avmapki Fakzynja Co-Pack AVUTOMETINIB marketed Oncology 2025-01-01
Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel phase 3 Chemotherapy combination (nucleoside analog + taxane) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Central European Cooperative Oncology Group · 1 shared drug class
  2. ERYtech Pharma · 1 shared drug class
  3. Hansoh BioMedical R&D Company · 1 shared drug class
  4. Pancreatic Cancer Action Network · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Verastem, Inc.:

Cite this brief

Drug Landscape (2026). Verastem, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/verastem-inc. Accessed 2026-06-10.

Related